|

Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

RECRUITINGPhase 3Sponsored by Sun Yat-sen University
Actively Recruiting
PhasePhase 3
SponsorSun Yat-sen University
Started2020-11-01
Est. completion2030-12-31
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05080010

Summary

The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Ability to provide written informed consent and comply with study assessments for the full duration of the study.
* Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.
* Received enucleation in the study eye.
* Monocular retinoblastoma.

Exclusion Criteria:

* Any previous disease in the study eye.
* Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
* History of chemical intervention for retinoblastoma in the study eye.

Conditions2

CancerRetinoblastoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.